David D Dickey
Overview
Explore the profile of David D Dickey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
293
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kruspe S, Dickey D, Urak K, Blanco G, Miller M, Clark K, et al.
Mol Ther Nucleic Acids
. 2017 Sep;
8:542-557.
PMID: 28918054
A challenge for circulating tumor cell (CTC)-based diagnostics is the development of simple and inexpensive methods that reliably detect the diverse cells that make up CTCs. CTC-derived nucleases are one...
2.
Steines B, Dickey D, Bergen J, Excoffon K, Weinstein J, Li X, et al.
JCI Insight
. 2016 Oct;
1(14):e88728.
PMID: 27699238
The physiological components that contribute to cystic fibrosis (CF) lung disease are steadily being elucidated. Gene therapy could potentially correct these defects. -null pigs provide a relevant model to test...
3.
Xu X, Dickey D, Chen S, Giangrande P
Methods
. 2016 Mar;
103:175-9.
PMID: 26972787
RNA aptamers represent an emerging class of biologics that can be easily adapted for personalized and precision medicine. Several therapeutic aptamers with desirable binding and functional properties have been developed...
4.
Thiel W, Esposito C, Dickey D, Dassie J, Long M, Adam J, et al.
Mol Ther
. 2016 Jan;
24(4):779-87.
PMID: 26732878
Inhibition of vascular smooth muscle cell (VSMC) proliferation by drug eluting stents has markedly reduced intimal hyperplasia and subsequent in-stent restenosis. However, the effects of antiproliferative drugs on endothelial cells...
5.
Dickey D, Giangrande P
Methods
. 2015 Dec;
97:94-103.
PMID: 26631715
A critical challenge for treating cancer is the early identification of those patients who are at greatest risk of developing metastatic disease. The number of circulating tumor cells (CTCs) in...
6.
Dickey D, Thomas G, Dassie J, Giangrande P
Methods Mol Biol
. 2015 Oct;
1364:209-17.
PMID: 26472453
RNA aptamers are single-stranded RNA oligos that represent a powerful emerging technology with potential for treating numerous diseases. More recently, cell-targeted RNA aptamers have been developed for delivering RNA interference...
7.
Sanders P, Koval O, Jaffer O, Prasad A, Businga T, Scott J, et al.
Sci Transl Med
. 2013 Jul;
5(195):195ra97.
PMID: 23884469
Increased reactive oxygen species (ROS) contribute to asthma, but little is known about the molecular mechanisms connecting increased ROS with characteristic features of asthma. We show that enhanced oxidative activation...
8.
Dickey D, Excoffon K, Young K, Parekh K, Zabner J
J Gene Med
. 2012 May;
14(6):366-73.
PMID: 22610695
Background: In airway epithelia, the kinetics of recombinant adeno-associated virus (AAV) transgene expression is slow. This has negative practical implications for research, as well as for translation into therapy. The...
9.
Dickey D, Excoffon K, Koerber J, Bergen J, Steines B, Klesney-Tait J, et al.
J Virol
. 2011 Jun;
85(17):9023-30.
PMID: 21697483
We previously used directed evolution in human airway epithelia to create adeno-associated virus 2.5T (AAV2.5T), a highly infectious chimera of AAV2 and AAV5 with one point mutation (A581T). We hypothesized...
10.
Excoffon K, Koerber J, Dickey D, Murtha M, Keshavjee S, Kaspar B, et al.
Proc Natl Acad Sci U S A
. 2009 Feb;
106(10):3865-70.
PMID: 19237554
Respiratory viruses evolve to maintain infectivity levels that permit spread yet prevent host and virus extinction, resulting in surprisingly low infection rates. Respiratory viruses harnessed as gene therapy vectors have...